Evidence suggests that multiple genetic and environmental factors conspire together to increase susceptibility to Alzheimer's disease (AD). The amyloid cascade hypothesis states that deposition of the amyloid-b (Ab) peptide is central to AD; however, evidence in humans and animals suggests that Ab buildup alone is not sufficient to cause neuronal cell loss and cognitive decline. Mouse models that express high levels of mutant forms of amyloid precursor protein and/or cleaving enzymes deposit amyloid but do not show neuron loss. Therefore, a double-hit hypothesis for AD has been proposed whereby vascular dysfunction precedes and promotes Ab toxicity. In support of this, copy number variations in mesenchyme homeobox 2 (MEOX2), a gene involved in vascular development, are associated with severe forms of AD. However, the role of MEOX2 in AD has not been studied. Here, we tested Meox2 haploinsufficiency in B6.APP/PS1 (B6.APB Tg ) mice, a mouse model of AD. Despite no overt differences in plaque deposition or glial activation, B6.APB Tg mice that carry only one copy of Meox2 (B6.APB
Introduction
Alzheimer's disease (AD), a leading cause of dementia, is a complex disease characterized by severe cognitive deficits, neuronal loss, and ultimately death. Accumulation of amyloid-b (Ab) peptide and plaque deposition in the brain and blood vessel walls are distinctive features of AD that are likely to occur in part as a consequence of neurovascular breakdown (Zlokovic, 2011) . Recent evidence supports a significant role of cerebrovascular dysfunction in AD pathogenesis, including severe brain microvascular pathology, angiogenesis impairment, deficits in Ab peptide clearance through the blood brain barrier (BBB), and cerebral amyloid angiopathy (Brown and Thore, 2011; Farkas and Luiten, 2001; Grammas, 2011; Zlokovic, 2011) . In addition, it is known that vascular risk factors such as diabetes, hypertension, obesity, and cardiovascular disease predispose individuals to AD (Dewey and Saz, 2001; Knopman and Roberts, 2010; Norton et al., 2014) , possibly by decreasing cerebral blood flow (CBF) and promoting hypoperfusion-hypoxia in the brain (Brown and Thore, 2011; Farkas and Luiten, 2001; Grammas, 2011; Zlokovic, 2011) . More importantly, in vivo imaging studies in humans have demonstrated that early cerebrovascular hypoperfusion precedes Ab accumulation and brain atrophy in AD and is associated with cognitive decline (Iadecola, 2004; Knopman and Roberts, 2010; Zlokovic, 2011) , suggesting that early neurovascular pathology and dysfunction lead to neuronal failure and neurodegeneration.
In recent years, increasing evidence in animal models and human brains from AD patients have demonstrated how molecular and cellular events that lead to neurovascular dysfunction influence and interact with other pathologic processes in AD, including Ab accumulation and tau pathology Sagare et al., 2013; Sengillo et al., 2013; Winkler et al., 2015; Zhao et al., 2015) . It has been found that genetically induced loss of pericytes in amyloid precursor protein (APP)-overexpressing mice causes BBB breakdown, increased levels of Ab plaque deposition, and extensive loss of neurons (Sagare et al., 2013) . In addition, extensive loss of pericytes and BBB breakdown were evident in human brains from AD patients carrying the apolipoprotein E4 (APOE4) gene . Also, reduced expression of PICALM, a genetic risk factor for AD, is associated with reductions in clearance of Ab and cognitive impairments . More recently, it was found that genetic reduction of the glucose transporter GLUT1 in brain endothelial cells from mice overexpressing APP caused BBB breakdown, increased levels of Ab plaque deposition, and significant neuronal loss . Collectively, these studies strongly support an early and significant role of neurovascular disruption in AD onset and progression. In line with these findings, a two-hit vascular hypothesis has been proposed, postulating that vascular risk factors (that are increased by age) induce BBB breakdown and/or hypoperfusion, thus disrupting Ab clearance and neurotoxicity (Zlokovic, 2011) . Ab deposition may also amplify the neurovascular injury by disrupting angiogenic responses in brain endothelial cells and promoting blood vessel elimination, leading to neuronal dysfunction and neurodegeneration (Brown and Thore, 2011; Grammas et al., 2011) .
Genetic risk factors are important contributors to AD development. A recent genome-wide association study identified rare copy number variations associated with early and severe phenotypes of AD (Rovelet-Lecrux et al., 2012) . The study identified copy number variations in the homeobox protein mesenchyme homeobox 2 (MEOX2), a gene expressed by the vascular system that plays a major role in vascular differentiation (Gorski and Walsh, 2003) . MEOX2 expression is downregulated in brain endothelial cells from AD patients, and reduced levels of MEOX2 cause aberrant angiogenic responses in human and mouse endothelial cells (Wu et al., 2005) . However, the impact of Meox2 haploinsufficiency in mouse models of AD remains to be tested.
As copy number variations in MEOX2 are associated with early and severe phenotypes of AD, in this study, the contribution of Meox2 haploinsufficiency (i.e., one copy of Meox2) to AD pathology in C57BL/6J.APP swe PSEN1 de9 (Jankowsky et al., 2004, herein referred to as B6.APB Tg ) mice was assessed. B6.APB Tg mice haploinsufficient for Meox2 presented significant neuronal degeneration and cognitive decline that correlated with a loss of microvessels, particularly in regions of Ab plaque deposition. This suggests that Meox2 haploinsufficiency may sensitize endothelial cells to Ab toxicity and further supports a contribution of vascular dysfunction to AD susceptibility and pathology.
Materials and methods

Mouse strains and cohort generation
All experiments involving mice were conducted in accordance with policies and procedures described in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and were approved by the Institutional Animal Care and Use Committee at The Jackson Laboratory. All mice were bred and housed in a 12/12 hour light/dark cycle. All experiments were performed on a unified genetic background (C57BL/6J). C57BL/6J mice heterozygous for the insertion of the cre-recombinase gene in place of the Meox2 gene were obtained from The Jackson Laboratory (B6.129S4-Meox2
CreSor , JAX stock #003755). The Cre insertion ablates the transcription of the Meox2 gene creating a Meox2 null allele (Mx observed at these later ages (10 and 14 months). Therefore, data from male and female mice were combined.
Spatial working memory tests using the Y-maze
Behavioral tests were performed in the Mouse Neurophenotyping Behavioral Facility at The Jackson Laboratory. To test spatial working memory, spontaneous alternation behavior was assessed using the Y-maze test. Each group of mice was compared with the other experimental/control groups and also to chance levels (50%) as reported by others (Bertholet and Crusio, 1991; Hooper et al., 1996; Jacquelin et al., 2012) . At the beginning of trials, mice were placed midway in the start arm and allowed to freely explore the 3 arms for 8 minutes. The sequence of arm entries was recorded by a ceiling-mounted video camera and analyzed with Ethovision software (Noldus). The maze was cleaned with 1% Virkon before the tests began and between animals to eliminate traces of odor. The number of arm entries and the number of triads (defined as entries into the 3 different arms of the Y-maze without returning to a previously visited arm, Drew et al., 1973; Hughes, 2004) were recorded to calculate the alternation percentage. Only mice that performed >20 arm entries were included in the analysis, to ensure that animals were engaged in active exploration of the maze.
Tissue harvesting, protein isolation, and sectioning
Mice were administered a lethal dose of ketamine/xylazine by intraperitoneal injection, in accordance to Institutional Animal Care and Use Committee protocols, and transcardially perfused with 1Â phosphate-buffered saline (PBS) at 4, 10, and 14 months of age. Brains were then dissected, the right hemisphere was snap frozen for protein isolation, and the left hemisphere was fixed in 4% paraformaldehyde overnight at 4 C, rinsed with 1Â PBS, cryoprotected first in 10% and then in 30% sucrose at 4 C, and embedded in optimal cutting temperature compound. Frozen brains were sectioned at 20 mm and stored at À80 C until required. Protein (for 6E10 and human Ab 42 measurements) was extracted with Trizol Reagent (Life Technologies cat#15596e018) following manufacturer's guidelines. Pellets were resuspended in a solution of 1:1 8M urea and 1% sodium dodecyl sulfate. Additional samples were extracted via RIPA lysis buffer (Sigma-Aldrich) for MEOX2 Western blots.
Immunofluorescence and Thioflavin S staining
Brain sections were incubated 2 nights at 4 C in the following primary antibodies: goat polyclonal anti-CD31 (1:40; R&D Systems), Biotinylated Lycoperiscon Esculentum (Tomato) Lectin (1:200; Vector), chicken polyclonal anti-glial fibrillary acidic protein (GFAP) (1:200; Acris Antibodies), rabbit polyclonal anti-IBA1 (also known as allograft inflammatory factor [AIF1]) (1:200; Wako), rat monoclonal CD68 (1:200; AbD Serotec), sheep polyclonal TREM2 (1:100; R&D Systems), laminin A2 (LAMA2) (1:100; Abcam), and mouse anti NEUN (1:200; Millipore). All antibodies were diluted in 1Â PBS and 1% TritonX-100 containing 10% normal donkey serum. After primary incubation, sections were washed 3 times in 1Â PBS and 1% TritonX-100 and incubated with their respective secondary antibody (donkey anti-chicken Alexa Fluor 633, donkey anti-rabbit Alexa Fluor 488/594, donkey anti-goat Alexa Fluor 488/594, donkey anti-rat Alexa Fluor 594, donkey anti-mouse Alexa Fluor 488/633, Streptavidin Alexa 488/633, 1:1000 dilution; Life Technologies) for 2 hours at room temperature. All sections were then counterstained with 4',6-diamidino-2-phenylindole and mounted with Aqua PolyMount. For Thioflavin S staining, sections stained with antibodies raised against IBA1 and GFAP or lectin were further counterstained with 1% Thioflavin S (diluted in a 1:1 water:ethanol ratio). Slides were incubated for 8 minutes at room temperature in 1% Thioflavin S, washed in 80% ethanol, then in 95% ethanol, and finally in dH 2 O, and mounted. Images were taken using either the Leica SP5 confocal microscope or the Zeiss Axio Imager Z2, located within the Imaging facility at The Jackson Laboratory.
Image quantitative analyses
Quantifications were performed as follows. For plaque counts, the number of plaques present in the entire cortical region from a central section for each mouse was determined. For quantification of IBA1 þ cells in the cortex, 4 images (Â20, 1388 Â 1040 microns)
were taken for each brain from each mouse with a Zeiss Axio Imager fluorescent microscope, and cells were manually counted using the cell counter plugin from ImageJ ( Neuron (NEUNþ), microvessel (LAMA2), and plaque/microvessel (lectin) area were calculated separately. As the lectin area contained plaque and microvessel area, plaque area alone was calculated as lectin area e LAMA2 area. In all cases, area was calculated using specially designed algorithms that have been described and validated previously and are available on request.
Western blotting
Protein levels of human APP in transgenic mice were measured using Western blotting. Protein sample concentration was determined via DC assay (Bio-Rad), and a total of 1.5 mg of the protein was used for this analysis. Samples were heated to 95 C for 5 minutes and then loaded onto a 12% TGX stain-free gel (Bio-Rad). Gels were run at 150 V for 45 minutes and then transferred to a nitrocellulose membrane (Life Technologies) via the iBlot for 7 minutes. Blots were then incubated for 2 nights to a blocking solution (5% skim milk powder block in 0.1% PBS-Tween) with 6E10 antibody (1:2000, Covance/BioLegend) or Meox2 (1:1000) at 4 C. Blots were then washed 3 times in 0.1% PBS-Tween and incubated in the appropriate secondary antibody (anti-mouse IgG 1:30,000; Millipore) for 2 hours at room temperature. Detection was carried out using ECL detection reagents (GE Healthcare). Blots were treated with 0.25% sodium azide, thoroughly washed, further probed with anti-beta actin (1:1000; Abcam) in 0.1% PBS-Tween overnight at 4 C, washed 3 times, incubated with secondary antibody (anti-mouse IgG 1:30,000; Millipore) for 2 hours at room temperature, washed, and detected.
Enzyme-linked immunosorbent assay
Human Ab 42 levels were determined using the enzyme-linked immunosorbent assay (ELISA) detection kit from Life Technologies (cat#KHB3442) following the specified instructions. Protein samples from 14emonth-old mouse brains were diluted 1:50 in standard diluent buffer to ensure that urea and sodium dodecyl sulfate levels were compatible with the ELISA kit (see protein isolation details at Section 2.3). Samples were then compared with a standard curve, and Ab42 concentrations were established against the samples' protein concentrations following manufacturer's recommendations.
Statistical analysis
Data were analyzed using GraphPad Prism software. Significance was calculated using unpaired t tests for comparisons between 2 groups and 1-way multifactorial analysis of variance followed by Tukey post hoc tests for multiple comparisons. p Values are provided as stated by GraphPad, and significance was determined with p values <0.05.
Results
Mice carrying only 1 copy of Meox2 (B6.Mx À/þ mice, see
Section 2) were used to determine the contribution of Meox2 haploinsufficiency to AD-related pathology. Western blots confirmed that MEOX2 protein levels were reduced by w50% in the brains of 4-month-old B6.Mx À/þ mice compared with wild-type Fig. 1A) . A previous study reported reductions in cerebral microvessels and in cortical CBF in mice haploinsufficient for Meox2 (Wu et al., 2005) . In line with these previous findings, we also found a small but significant reduction in CD31 þ microvessels in our 4-month-old B6.Mx À/þ mice compared with B6 mice (Fig. 1B) . However, in contrast to previous findings, no differences in the number of cortical NEUN þ neurons were found between 10-month-old-B6.Mx À/þ and B6 mice (Fig. 1C) , and B6.APB Tg ) were established and aged to 14 months, and spatial working memory was examined using a Y-maze ( Fig. 2A and B (Fig. 2CeF) . Interestingly, neuronal cell loss was not observed in a second cohort of 10-month-old B6.APB Tg .Mx À/þ mice (data not shown), suggesting that neuronal cell loss occurred between 10 and 14 months of age. Scale bars: 500 mm (top panels) and 100 mm (bottom panels).
Meox2 haploinsufficiency does not alter Ab production, plaque deposition, or glia activation in B6.APB Tg mice
To begin to determine the mechanism(s) through which Meox2 haploinsufficiency causes neuronal cell loss in B6.APB Tg mice, plaque load was assessed in B6.APB Tg .Mx À/þ and B6.APB Tg mice at both 10 and 14 months of age. Immunoblotting using 6E10, an antibody that binds human APP protein and its fragments, showed no significant differences in human soluble APP levels between B6.APB Tg .Mx À/þ and B6.APB Tg mice (Fig. 3A) . Similarly, no differences were found in human Ab 42 levels (by ELISA, Fig. 3B Because Meox2 haploinsufficiency causes reductions in microvessels from a young age (Fig. 1) , we analyzed the area of microvessels (using CD31, a marker of endothelial cells, see Section 2) in the cortex and hippocampus (CA1 region) of B6.APB Tg .Mx À/þ and control mice at 10 and 14 months of age (Fig. 6A) . As expected, the area of cortical and CA1 microvessels immunolabeled with CD31 was significantly reduced in both B6.APB Tg .Mx À/þ and B6.Mx À/þ mice compared with B6 and B6.APB Tg mice ( Fig. 6B and C) Previous studies have shown that plaque deposition disrupts microvessels (Brown and Thore, 2011; Grammas et al., 2011; Kelleher and Soiza, 2013; Zlokovic, 2011) . Therefore, we hypothesized that microvessel loss in B6.APB
Tg
.Mx
À/þ mice would be greatest in regions containing plaques. To test this, brain sections from B6.APB Tg .Mx À/þ and controls at 14 months of age were immunolabeled with LAMA2, a basement membrane protein that identifies microvessels, and lectin, a protein that binds to cell membranes and conveniently labels microvessels (Mazzetti et al., 2004) . In addition, strong immunoreactivity of lectin was found in microglia clusters surrounding the amyloid plaques ( Fig. 7A and 8A ) and when combined with LAMA2 allows simultaneous assessment of microvessel and plaque area (see Section 2). There was no significant difference in the area of LAMA2 þ microvessels in B6.APB Tg mice compared with B6 mice (Fig. 8B ). However, a significant reduction in LAMA2 þ microvessel area surrounding plaques was found in B6.APB Tg .Mx À/þ mice compared with B6.APB Tg mice (Fig. 8B) . This difference was not because of changes in plaque size (Fig. 8C) . We next determined whether the combination of microvessel reduction and plaque deposition in B6.APB Tg .Mx À/þ mice could be intensifying the loss of neurons in B6.APB Tg .Mx
compared with control mice. NEUN þ neurons were quantified specifically in regions of activated IBA1 þ microglia clusters surrounding plaques (Fig. 8D ). There was a significant reduction in NEUN þ neurons surrounding plaques in B6.APB Tg .Mx À/þ mice compared with B6.APB Tg mice (Fig. 8E) , which was independent of plaque area (Fig. 8F) . Therefore, Meox2 haploinsufficiency and plaque deposition had a synergistic neurotoxic effect in B6.APB Tg .Mx À/þ mice.
Discussion
It is thought that pathologic neurovascular irregularities and vascular risk factors are important contributors to the onset and progression of AD. Several reports have shown severe pathologic changes in the cerebral vasculature (Buee et al., 1994; Farkas and Luiten, 2001; Grammas, 2011; Halliday et al., 2015; Sagare et al., 2012; Zlokovic, 2005) and associated vascular-related genetic risk factors (Bell, 2012; Winkler et al., 2015; Zhao et al., 2015; Zlokovic, 2010) with AD development and progression. Vascular-related genes have been found to be both affected by AD (e.g., GLUT1 and LRP) and identified as genetic risk factors for disease development (e.g., APOE, MEOX2, MYOCD, and PICALM) (Bell, 2012; Mahley et al., 2009; Sagare et al., 2012; Zlokovic, 2010) . In the case of MEOX2, rare copy number variants for this gene are associated with a severe form of AD in humans (Rovelet-Lecrux et al., 2012) . Furthermore, MEOX2 expression is downregulated in endothelial cells from brains of AD patient, and these cells were found to be dysfunctional and pro-apoptotic in in vitro assays of vascular tube formation (Wu et al., 2005) . In addition, previous studies (Wu et al., 2005) , confirmed in our study here (Fig. 1) , showed that haploinsufficiency of MEOX2 in mice led to microvascular reductions in the brain. Given the association of copy number variations of MEOX2 with severe forms of AD (Rovelet-Lecrux et al., 2012) , this suggests MEOX2-mediated vascular dysfunction may be a contributing factor in AD. amyloid plaque deposition and neuroinflammation, but, in the absence of additional genetic manipulations, not many show significant neuronal loss and associated cognitive decline (Onos et al., 2015; Webster et al., 2014; Wirths and Bayer, 2010) . The lack of substantial neuronal cell loss significantly limits the identification and testing of therapeutic targets for AD (Onos et al., 2015) . However, recent studies have shown that combinatorial approaches that disrupt neurovascular function in addition to promoting Ab plaque deposition can induce neuronal cell loss and some cognitive impairment (Sagare et al., 2013; Winkler et al., 2015; Zhao et al., 2015) . In our study, Meox2 haploinsufficiency caused early reductions in microvessel density that did not promote neuronal loss (Fig. 1) . However, when combined with mutant APP and PSEN1 proteins, Meox2 haploinsufficiency caused significant neuronal loss (Fig. 2) , particularly around plaques (Fig. 8) Ab toxicity, as a mild reduction in CBF can disrupt important neuronal functions, such as protein synthesis (Iadecola, 2004; Zlokovic, 2011) . Furthermore, it is possible that CBF could be even more compromised in B6.APB Tg .Mx À/þ mice because of the deposition of Ab, leading to an additional loss of microvessels and increased neuronal toxicity. An alternative explanation is that decreased levels of Meox2 in endothelial cells may disrupt Ab clearance. Ab is cleared by the vascular system through the low-density lipoprotein 1 (LRP1) receptor. Reduced levels of LRP1 receptor as a result of microvessel loss would result in potential accumulation of Ab on blood vessels (Wu et al., 2005; Zlokovic, 2010; Zlokovic et al., 2010) . Although in our study, we saw no significant differences in overall plaque load between B6.APB Tg .Mx À/þ and B6.APB Tg mice; therefore, this explanation seems unlikely. However, given that neurons are the main producers of mutant human APP in the mouse model used here (Borchelt et al., 1997) , it is possible that B6.APB Tg .Mx À/þ has an increased ratio of APP production per neuron as we did not observe a decrease in APP levels (Fig. 3A ) despite observing neuronal cell loss (Fig. 2) . Interestingly, by considering the ratio of plaque load to APPproducing neuronal cell number between B6.APB (Wu et al., 2005) , whereas Meox2 is not downregulated in endothelial cells during disease progression in mouse models of AD where neuronal cell loss is not normally observed. This lack of a reduction in MEOX2 protein in mouse models of AD may cause a robustness of mouse cerebral endothelial cells in response to plaque load and override the neurotoxic effects of Ab plaque deposition observed in humans (Deshpande et al., 2006; Donev et al., 2009; Urbanc et al., 2002; Yankner et al., 1989) . This robustness could be lessened by Meox2 haploinsufficiency, causing further loss of vascular endothelial cells and neurons in these plaque regions. This mechanism could also account for the association between copy number variations involving MEOX2 with severe phenotypes in human AD (Rovelet-Lecrux et al., 2012).
The reduction in vascular density in the brain caused by a combination of Meox2 haploinsufficiency and Ab deposition could be an important contributor to cerebral hypoperfusion in AD (Brown and Thore, 2011; Farkas and Luiten, 2001; Grammas, 2011; Zlokovic, 2005) . Cerebral hypoperfusion has been considered a major contributor to cognitive impairment and AD development and pathology. CBF has been seen to be reduced in the initial stages of AD when early cognitive impairment is detected, which suggests that vascular dysfunction precedes neuronal degeneration and brain atrophy (Hirao et al., 2005; Johnson et al., 2005; Pakrasi and O'Brien, 2005) . One possible mechanism is that decreased CBF and altered uptake and utilization of glucose and oxygen (Brown and Thore, 2011; Farkas and Luiten, 2001; Grammas, 2011; Zlokovic, 2005) can lead to impairments in neuronal metabolism and function (Farkas and Luiten, 2001; Hermann et al., 2001; Zlokovic, 2011) causing cognitive decline and neurodegeneration.
In conclusion, our study shows that Meox2 haploinsufficiency mediates amyloid dependent neuronal cell loss and Y-maze deficits, possibly by effecting microvessels surrounding plaques. Hence, therapies that include preservation of microvessels should be considered for human AD.
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